ENSG Ensign (ENSG) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-skilled nursing care facilities · CIK 0001125376
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
254
13F, latest reported quarter
What the filings say about ENSG
Insiders, 180 days
-$413.2K net sold
4 sellers · 14% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$18.0K
1 notice
Ensign insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, ENSIGN GROUP, INC insiders sold a net $413.2K of stock across 178 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Jul 16, 2026.
- The trade is 2.3% of the 4,400 shares held after it.
- No other insider sold within 30 days.
- 254 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Parkinson Mark Vincent sold about $18.0K of ENSG under a 10b5-1 plan on Oct 16, 2026; 254 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Feb 9, 2026.
- The trade is 0.7% of the 23,877 shares held after it.
- 2 other insiders sold within 30 days.
- 254 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Blouin Ann Scott sold about $31.8K of ENSG on Jul 27, 2026; 2 other insiders sold within 30 days and 254 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Feb 9, 2026.
- The trade is 0.8% of the 23,677 shares held after it.
- 2 other insiders sold within 30 days.
- 254 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Blouin Ann Scott sold about $37.0K of ENSG on Jul 27, 2026; 2 other insiders sold within 30 days and 254 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (1 buy, 4 sales), the last on Apr 20, 2026.
- The trade is 4.1% of the 9,503 shares held after it.
- 2 other insiders sold within 30 days.
- 254 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Agwunobi John O sold about $67.1K of ENSG on Jul 20, 2026; 2 other insiders sold within 30 days and 254 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Apr 16, 2026.
- The trade is 2.6% of the 3,900 shares held after it.
- 2 other insiders sold within 30 days.
- 254 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Parkinson Mark Vincent sold about $16.8K of ENSG on Jul 16, 2026; 2 other insiders sold within 30 days and 254 funds added in the latest 13F quarter.178 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$413.2K over 180 days
-$18.0K over 90 days
more than 62% of Healthcare Services
Congress
no House purchase disclosed in the last 12 months
Funds
254 funds bought in last quarter
more than 83% of Healthcare Services
Revenue
+18.8% year over year
more than 66% of Healthcare Services
Margin
6.8% net margin
more than 78% of Healthcare Services
Buybacks
$40.0M repurchased, FY to 2026-06-30
below 58% of Healthcare Services
Short interest
2.5% of the float short (float per yahoo 2026-10-27) · 4.0 days to cover · settled 2026-10-15
below 58% of Healthcare Services
What changed in the last 30 days
Oct 19Director Parkinson Mark Vincent sold $18.0K under a 10b5-1 plan (Oct 16)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 16Director Parkinson Mark Vincent filed to sell $18.0K by Oct 16 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch ENSG
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-4.5%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns ENSG: institutional holders (13F)
13F holdings, latest reported quarter
5,846,650 sh
$937.2M
5,029,273 sh
$806.2M
2,866,559 sh
$459.5M
2,624,612 sh
$420.7M
2,540,352 sh
$407.2M
Congress trades in ENSG
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
ENSG planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Parkinson Mark Vincent
Filed 2026-10-16
$18.0K
Blouin Ann Scott
Filed 2026-07-27
$68.8K
Agwunobi John O
Filed 2026-07-20
$67.1K
Parkinson Mark Vincent
Filed 2026-07-16
$16.8K
ENSG mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Bahl & Gaynor Small Cap Dividend ETF
$11.3M position · as of 2026-06-30
7.4%
Value Line Small Cap Opportunities Fund, Inc.
$33.7M position · as of 2026-06-30
4.1%
Wasatch Long/Short Alpha Fund
$1.4M position · as of 2026-06-30
3.8%
Wasatch Small Cap Growth Fund
$44.2M position · as of 2026-06-30
3.8%
Paradigm Micro-Cap Fund
$6.4M position · as of 2026-06-30
3.5%
Wasatch U.S. Select Fund
$550.8K position · as of 2026-06-30
3.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Port
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$13.8M
$16.3M
$8.1M
+141%
+128%
2024
$11.0M
$11.5M
$7.2M
+197%
+58%
2023
$11.0M
$9.7M
$7.4M
+150%
+14%
2022
$8.0M
$8.0M
$5.3M
+110%
-12%
2021
$7.4M
$7.5M
$4.9M
+86%
+3%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $413.2K sold by insiders over 180 days, 254 funds added last quarter, $18.0K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
ENSG financials
Revenue growth
+18.8%
XBRL, annual
Net margin
6.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.5B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM ENSG
| FY Dec 2025 | $5.1B |
| FY Dec 2024 | $4.3B |
| FY Dec 2023 | $3.7B |
| FY Dec 2022 | $3.0B |
| FY Dec 2021 | $2.6B |
| Jun 2026 | $1.4B |
| Mar 2026 | $1.4B |
| Dec 2025 | $1.4B |
| Sep 2025 | $1.3B |
| Jun 2025 | $1.2B |
| Mar 2025 | $1.2B |
| Dec 2024 | $1.1B |
| Sep 2024 | $1.1B |
At each fiscal year end
Single quarter
Net margin, TTM
+6.9%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM ENSG
| FY Dec 2025 | +6.8% |
| FY Dec 2024 | +7.0% |
| FY Dec 2023 | +5.6% |
| FY Dec 2022 | +7.4% |
| FY Dec 2021 | +7.4% |
| Jun 2026 | +6.9% |
| Mar 2026 | +7.2% |
| Dec 2025 | +7.0% |
| Sep 2025 | +6.5% |
| Jun 2025 | +6.9% |
| Mar 2025 | +6.8% |
| Dec 2024 | +7.0% |
| Sep 2024 | +7.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$536.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM ENSG
| FY Dec 2025 | $492.7M |
| FY Dec 2024 | $275.6M |
| FY Dec 2023 | $305.1M |
| FY Dec 2022 | $201.0M |
| FY Dec 2021 | $204.1M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.06x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity ENSG
| FY Dec 2025 | 0.06x |
| FY Dec 2024 | 0.08x |
| FY Dec 2023 | 0.10x |
| FY Dec 2022 | 0.12x |
| FY Dec 2021 | 0.15x |
| Jun 2026 | 0.06x |
| Mar 2026 | 0.06x |
| Dec 2025 | 0.06x |
| Sep 2025 | 0.07x |
| Jun 2025 | 0.07x |
| Mar 2025 | 0.08x |
| Dec 2024 | 0.08x |
| Sep 2024 | 0.08x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
4.35x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt ENSG
| FY Dec 2025 | 3.98x |
| FY Dec 2024 | 2.38x |
| FY Dec 2023 | 2.52x |
| FY Dec 2022 | 1.78x |
| FY Dec 2021 | 1.76x |
| Jun 2026 | 4.35x |
| Mar 2026 | 4.21x |
| Dec 2025 | 3.98x |
| Sep 2025 | 3.37x |
| Jun 2025 | 3.22x |
| Mar 2025 | 2.65x |
| Dec 2024 | 2.38x |
| Sep 2024 | 2.26x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+17.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity ENSG
| FY Dec 2025 | +16.9% |
| FY Dec 2024 | +17.9% |
| FY Dec 2023 | +15.3% |
| FY Dec 2022 | +19.8% |
| FY Dec 2021 | +21.2% |
| Jun 2026 | +17.0% |
| Mar 2026 | +16.9% |
| Dec 2025 | +16.9% |
| Sep 2025 | +17.0% |
| Jun 2025 | +17.6% |
| Mar 2025 | +17.7% |
| Dec 2024 | +17.9% |
| Sep 2024 | +15.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+7.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets ENSG
| FY Dec 2025 | +6.8% |
| FY Dec 2024 | +6.7% |
| FY Dec 2023 | +5.5% |
| FY Dec 2022 | +7.1% |
| FY Dec 2021 | +7.2% |
| Jun 2026 | +7.1% |
| Mar 2026 | +7.0% |
| Dec 2025 | +6.8% |
| Sep 2025 | +6.7% |
| Jun 2025 | +6.9% |
| Mar 2025 | +6.8% |
| Dec 2024 | +6.7% |
| Sep 2024 | +5.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+17.3%
operating income after a 24.0% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital ENSG
| FY Dec 2025 | +19.0% |
| FY Dec 2024 | +20.9% |
| FY Dec 2023 | +17.8% |
| FY Dec 2022 | +23.1% |
| FY Dec 2021 | +24.1% |
| Jun 2026 | +17.3% |
| Mar 2026 | +18.2% |
| Dec 2025 | +19.0% |
| Sep 2025 | +19.3% |
| Jun 2025 | +19.3% |
| Mar 2025 | +19.3% |
| Dec 2024 | +20.9% |
| Sep 2024 | +17.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+10.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed ENSG
| FY Dec 2025 | +10.0% |
| FY Dec 2024 | +9.7% |
| FY Dec 2023 | +8.1% |
| FY Dec 2022 | +11.4% |
| FY Dec 2021 | +12.1% |
| Jun 2026 | +10.3% |
| Mar 2026 | +10.2% |
| Dec 2025 | +10.0% |
| Sep 2025 | +9.7% |
| Jun 2025 | +10.0% |
| Mar 2025 | +9.9% |
| Dec 2024 | +9.7% |
| Sep 2024 | +7.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
27.73x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing ENSG
| FY Dec 2025 | 29.83x |
| FY Dec 2024 | 26.00x |
| FY Dec 2023 | 30.74x |
| FY Dec 2022 | 23.95x |
| FY Dec 2021 | 24.55x |
| Jun 2026 | 25.13x |
| Mar 2026 | 32.82x |
| Dec 2025 | 29.83x |
| Sep 2025 | 30.91x |
| Jun 2025 | 28.00x |
| Mar 2025 | 24.46x |
| Dec 2024 | 26.00x |
| Sep 2024 | 34.91x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$10.2B
market value at close 2026-10-26 on 2026-07-23 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value ENSG
| FY Dec 2025 | $9.7B |
| FY Dec 2024 | $7.3B |
| FY Dec 2023 | $6.0B |
| FY Dec 2022 | $5.1B |
| FY Dec 2021 | $4.5B |
| Jun 2026 | $9.2B |
| Mar 2026 | $11.3B |
| Dec 2025 | $9.7B |
| Sep 2025 | $9.7B |
| Jun 2025 | $8.6B |
| Mar 2025 | $7.3B |
| Dec 2024 | $7.3B |
| Sep 2024 | $7.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.2%
TTM free cash flow over market value at close 2026-10-26
FCF yield ENSG
| FY Dec 2025 | +4.9% |
| FY Dec 2024 | +3.6% |
| FY Dec 2023 | +4.8% |
| FY Dec 2022 | +3.8% |
| FY Dec 2021 | +4.4% |
| Jun 2026 | +5.7% |
| Mar 2026 | +4.4% |
| Dec 2025 | +4.9% |
| Sep 2025 | +4.1% |
| Jun 2025 | +4.4% |
| Mar 2025 | +4.2% |
| Dec 2024 | +3.6% |
| Sep 2024 | +3.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.76x
P/E over trailing EPS growth of 16%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing ENSG
| FY Dec 2025 | 2.09x |
| FY Dec 2024 | 0.65x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 1.55x |
| FY Dec 2021 | 2.09x |
| Jun 2026 | 1.59x |
| Mar 2026 | 2.04x |
| Dec 2025 | 2.09x |
| Sep 2025 | 0.87x |
| Jun 2025 | 0.67x |
| Mar 2025 | 0.62x |
| Dec 2024 | 0.65x |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $5.1B | $4.3B | $3.7B | $3.0B |
| Operating income | $425.3M | $358.3M | $255.4M | $296.8M |
| Net income | $344.0M | $298.0M | $209.4M | $224.7M |
| EPS (diluted) | 5.84 | 5.12 | 3.65 | 3.95 |
| Operating cash flow | $564.3M | $347.2M | $376.7M | $272.5M |
| Cash | $503.9M | $464.6M | $509.6M | $316.3M |
| Long-term debt | $137.5M | $141.6M | $145.5M | $149.3M |
| Buybacks | $20.0M | $0 | $0 | $29.9M |
| Dividends paid | $14.4M | $13.7M | $12.9M | $12.2M |
SEC XBRL, fiscal years, as known on 2026-10-28
ENSG Stock Sonar score 6/7 axes
Find similar shapesCompareENSG ranks highest on financial health (85th percentile) and institutional and government (83rd), and lowest on insider conviction (30th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
ENSG filings, in plain words
Are Ensign insiders buying or selling ENSG?
In the 180 days to 2026-10-28, Ensign insiders were net sellers, a net $413.2K across purchases and sales reported on Form 4, by 4 sellers.
Are there planned insider sales of ENSG?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $18.0K of stock; the latest, by Parkinson Mark Vincent, was filed 2026-10-16.
Read the full summary
In the 180 days to 2026-10-28, Ensign insiders were net sellers of ENSG, a net $413.2K across purchases and sales reported on Form 4 by 4 sellers. 14% of the 7 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $18.0K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
